The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Transactions / A•••••• R••••••• A•••••••••

E••••••• C••••••••• G•••• Completes Acquisition of A•••••• R••••••• A•••••••••

Add-on acquisitionclosedadd-onannounced May 2, 2024closed May 2, 2024Fact
What happened
Target
A•••••• R••••••• A•••••••••
Platform
E••••••• C••••••••• G••••• I•••add-on basis: E••••••• is held by G•••• P•••• P••••••• (holding evidence https://www.gppfunds.com/private-equity/portfolio-case-studies/)
Control
Control
Share acquired
unknown
Industry
business_services / consulting
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
4 named
Buy side
Side not stated
  • G••••• G••••Managementconfirmed
    ““We are thrilled to welcome Peter and the rest of the talented ARA team to E••••••• and to offer our clients the expertise that ARA has built over nearly three decades,” said G••••• G••••, CEO of E•••••••.”
  • A•••••• R••••••• A•••••••••Targetconfirmed
    “E••••••• C••••••••• G••••• I••• (“E•••••••”), a leading biometrics Contract R••••••• Organization (“CRO”), today announced that it has acquired A•••••• R••••••• A••••••••• (“ARA”), a provider of data management and biostatistical consulting services for clinical trials.”
Evidence
“E••••••• C••••••••• G••••• I••• (“E•••••••”), a leading biometrics Contract R••••••• Organization (“CRO”), today announced that it has acquired A•••••• R••••••• A••••••••• (“ARA”), a provider of data management and biostatistical consulting services for clinical trials.”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 16, 2026
E••••••• C••••••••• G•••• Completes Acquisition of A•••••• R••••••• A••••••••• | Private Equity Intelligence | DFX